Azemobo Akhimien
Internal Medicine · Gastonia, NCNPI 1992760581
Payments from drug & device makers
Across 96 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$405
- Johnson & Johnson$366
- Astellas Pharma US Inc$105
- Mylan Specialty L.p.$79
- AstraZeneca$77
- Amgen$77
- plus $545 from 18 others
What the payments were for
- Food & beverage$1,58396%
- Education$734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $405 |
| Johnson & Johnson | 19 | $366 |
| Astellas Pharma US Inc | 3 | $105 |
| Mylan Specialty L.p. | 6 | $79 |
| AstraZeneca | 5 | $77 |
| Amgen | 5 | $77 |
| Lilly USA, LLC | 5 | $71 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Novo Nordisk | 3 | $48 |
| Abbott | 2 | $47 |
| Boehringer Ingelheim | 2 | $47 |
| Novartis | 3 | $42 |
| Pfizer | 3 | $38 |
| Circassia Inc. | 2 | $28 |
| Radius Health, Inc. | 1 | $28 |
| Nevro Corp. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,656 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 27 | $7,619 |
| EliquisApixaban | 24 | $7,164 |
| Memantine Hcl | 17 | $983 |
| Rosuvastatin Calcium | 15 | $675 |
| Levothyroxine Sodium | 29 | $596 |
| Gabapentin | 24 | $546 |
| Divalproex Sodium | 14 | $496 |
| Colchicine | 17 | $479 |
| Oxybutynin Chloride ErOxybutynin Chloride | 17 | $439 |
| Sertraline Hcl | 29 | $416 |
| Furosemide | 40 | $367 |
| Potassium Chloride | 15 | $365 |
| Fluticasone Propionate | 15 | $355 |
| Quetiapine Fumarate | 16 | $352 |
| Amlodipine Besylate | 24 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $366 | $7,61927 claims |
| PfizerEliquis | $38 | $7,16424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Gastonia
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.